Skip to content

Clinical evaluation of MAgnetic Resonance imaging in Coronary heart disease

Clinical evaluation of MAgnetic Resonance imaging in Coronary heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN77246133
Enrollment
750
Registered
2006-02-21
Start date
2006-02-27
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease Circulatory System Coronary heart disease

Interventions

Comparing non-invasive techniques for diagnosing coronary artery disease (ETT, SPECT and CMR) against invasive angiography. Patients who agree to take part in the study will initially undergo three in

Sponsors

British Heart Foundation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Ages between 35 and 79 years 2. Weight less than 110 kg 3. Suitable for coronary revascularisation if required 4. Clinically stable 5. In sinus rhythm

Exclusion criteria

Exclusion criteria: 1. Previous revascularisation 2. Evidence of crescendo angina or acute coronary syndrome 3. Contraindication to MRI imaging (pacemaker, intraorbital debris, intraauricular implants, intracranial clips) 4. Contraindication to adenosine infusion (regular adenosine antagonist medication, asthma/chronic obstructive pulmonary disease, second or third degree atrioventricular heart block, sino-atrial disease) 5. Aged less than 35 years 6. Weight greater than 100 kg 7. Non-sinus rhythm 8. Resting heart rate greater than 100 /min 9. Frequent ventricular ectopy (greater than 3 Ventricular Premature Beats [VPB] per minute) 10. Pregnancy 11. Known adverse reaction to adenosine or gadolinium contrast agent 12. Inability to lie supine for 60 minutes 13. Known chronic renal insufficiency

Design outcomes

Primary

MeasureTime frame
The diagnostic performance of MRI to detect significant CHD on x-ray angiography

Secondary

MeasureTime frame
1. The diagnostic performance of current standard clinical investigations of ETT and SPECT 2. The cost effectiveness of CMRI in a diagnostic strategy for the systematic investigation of patients with suspected CHD 3. Patient's preference of the different strategies for the investigation of suspected CHD

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Sep 17, 2026